Werewolf reports Q2 2026 financial results, cash down to $22M
Werewolf Therapeutics reported Q2 2026 financial results noting a decrease in cash position to $22.0 million, following completion of a $21.0 million collaboration revenue transaction with Jazz Pharmaceuticals.
View filing at SEC.gov →